April 8, 2008 - The first-in-man study funded by MIV Therapeutics Inc. (MIV) showed that MIV's VESTAsync stents ...
Stents Drug Eluting
This channel includes news and new technology innovations for drug eluting stents (DES). These drug coated stents were developed to solve a frequent problem with bare metal stents, which can cause neointimal hyperplasia (scar tissue growth) in some patients. The antiproliferative drugs used on DES prevent the growth of tissue. One downside of DES is the requirement for patients to take long-term antiplatelet therapy to prevent the possible formation of clots on these stents. Newer generation DES use technologies help the vessels heal faster, which may allow reduce the duration of dual antiplatelet therapy (DAPT), or use a single drug, usually eliminating aspirin. This section includes news for both metallic and bioresorbable drug-eluting stents and related clinical trial data.
April 8, 2008 - A study using Itamar Medical's Endo-PAT2000, an FDA-cleared device used to assess endothelial function ...
April 07, 2008
April 3, 2008 - Patients treated with the TAXUS Stent had significant reductions in one-year revascularization rates in ...
April 02, 2008April 1, 2008 - Despite the known increased rates of mortality and restenosis for diabetics versus non-diabetics in ...
April 01, 2008April 1, 2008 – Boston Scientific welcomed results from Abbott’s prospective, randomized, single blind, two-year SPIRIT ...
March 31, 2008April 1, 2008 – Boston Scientific announced results from an analysis two-year data from more than 7,000 patients in the ...
March 31, 2008April 1, 2008 — A large community-based registry of patients treated with drug eluting stents is providing important ...
March 31, 2008April 1, 2008 — Early results of the SPIRIT II study showed that the XIENCE V sstent was superior to the Taxus stent in ...
March 31, 2008April 1, 2008 — An angioplasty balloon coated with a drug that reduces renarrowing of the coronary arteries appears to ...
March 31, 2008March 31, 2008 - New evidence from a large randomized study is answering important questions about the best approach to ...
March 30, 2008March 31, 2008 - Although drug-eluting stents have become widely used for the treatment of stable coronary artery ...
March 30, 2008March 30, 2008 - One-year data from the ENDEAVOR IV trial showing strong clinical efficacy for Medtronic's Endeavor drug ...
March 29, 2008March 13, 2008 – Abbott’s fully bioabsorbable drug-eluting stent for the treatment of coronary artery disease ...
March 16, 2008Feature | Cristen C. Bolan
The Society for Cardiovascular Angiography and Interventions (SCAI) has partnered with the American College of ...
March 16, 2008March 11, 2008 - Abbott announced today that it has received CE Mark (Conformite Europeene) approval for a 2.25 mm ...
March 10, 2008© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now